1. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.
2. Uchechukwu K, Sampsona, MacRae F et al. Are statins diabetogenic? Curr Opin Cardiol 2011; 26 (4): 342–7.
3. Jonas Rutishauser. Statins in clinical medicine. Swiss Med Wkly 2011.
4. Cholesterol Treatment Trialists’ (CTT) Collaborators. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366 (9493): 1267–78.
5. Mills EJ, Wu P, Chong G et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011; 104 (2): 109–24.
6. Yehuda Kamari, Rafael Bitzur, Hofit Cohen et al. Should All Diabetic Patients Be Treated With a Statin? Diabetes Care 2009; 32 (2).
7. Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–8.
8. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160–78.
9. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44.
10. McCarron P, Greenwood R, Elwood P et al. The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II: risk factors for ischaemic stroke. Public Health 2001; 115: 12–20.
11. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31 (Suppl. 1): S12–54.
12. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110 (2): 227–39.
13. Justin W, Timbie PhD, Rodney A et al. Variation in the net benefit of aggressive cardiovascular risk factor control across the US diabetes population. Arch Intern Med 2010; 170 (12): 1037–44.
14. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504.
15. Wu J, Kraja AT, Oberman A et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens 2005; 18 (7): 935–42.
16. Zulman DM, Vijan S, Omenn GS, Hayward RA. The relative merits of population-based and targeted prevention strategies. Milbank Quarterly Dec 2008; 86 (4): 557–80.
17. Swapnil N, Rajpathak S, Dharam J et al. Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis. Diabetes Care 2009.
18. Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–62.
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
20. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16.
21. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico). Ital Heart J 2000; 1: 810–20.
22. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007.
23. Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155–63.
24. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30.
25. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149–58.
26. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.
27. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375 (9716): 735–42.
28. David D, Waters et al. Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. Results From 3 Large Randomized Clinical Trials. J Am Coll Cardiol 2011; 57: 1535–45.
29. Sukhija R, Prayaga S, Marashdeh M et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009; 57: 495–9.
30. Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 2011;305 (24): 2556–64.

О.М.Драпкина, А.Ф.Шептулина

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ